Tumor Treating Fields (TTFs) deliver low-intensity electric fields through adhesive skin arrays and have received approval for use in multiple oncology indications. The devices are accompanied by a care infrastructure that often includes 24/7 assistance, home deliveries and routine home-based interactions to change arrays. These operational characteristics are an important part of how TTFs are delivered in clinical practice and have implications for trial design and interpretation.
A central concern raised in the review is the absence of sham-controlled randomized trials for TTFs. For devices, sham controls play the role that placebo controls play for drugs: they help isolate the specific effect of the device from non-specific effects such as increased clinical attention, supportive care, or other components of the intervention pathway. Because TTF use typically involves intensive ancillary support, the authors argue that without sham-controlled trials the specific contribution of the electrical fields themselves cannot be separated from the benefit that might arise from the additional care and interactions surrounding device delivery.
The authors note that, although a mechanistic rationale for TTFs exists, biological plausibility is constrained by limited empirical human data—most notably the lack of validated human in vivo dosimetry measurements. Validated dosimetry in humans would help confirm that the intended field strengths and distributions are achieved in target tissues, and clarify the relationship between device parameters and biological effects. The review states that such validated in vivo measurements are currently absent from the evidence base, limiting confidence in the mechanistic underpinnings of observed clinical effects.
The review examined six pivotal randomized trials that underpin the TTF evidence base. The authors report that half of these trials used what they describe as suboptimal control arms, and they highlight that two trials reporting a survival gain had suboptimal comparators. This raises uncertainty about whether reported benefits would remain if TTFs were tested against optimal, contemporary standard-of-care treatments and in settings with full access to such therapies. The review emphasizes that the choice and quality of control arms materially affect interpretation of efficacy outcomes in device trials.
Observed instances of protocol changes and unusual censoring patterns are described in the review and flagged as warranting further examination. The authors suggest that these trial conduct and analysis elements require scrutiny because they can influence outcomes and interpretation. The review also notes that post-market evidence generation for devices such as TTFs has not been sufficiently transparent, complicating independent assessment of longer-term effectiveness and safety in routine practice.
The authors discuss how regulatory frameworks for medical devices permit greater evidentiary flexibility than those typically applied to drugs. This flexibility can result in different thresholds for premarket approval and post-market obligations. The review calls attention to the relative lack of transparent post-market data and harmonized obligations for devices. The authors additionally note that, unlike many other device areas, the principal evidence supporting TTFs has been generated by a single company, with no substantial replication of results from competing manufacturers reported to date. This concentration of the evidence base is highlighted as a limitation when assessing generalizability and independent reproducibility.
The review concludes that the current evidence base for TTFs is limited by four interrelated issues: the absence of sham-controlled randomized trials, constrained biological plausibility due to missing validated human dosimetry, use of suboptimal control arms in several pivotal randomized trials, and trial conduct or analysis features (protocol changes and unusual censoring) requiring further scrutiny. To address these gaps the authors recommend the conduct of high-quality sham-controlled trials and the establishment of harmonized, transparent post-market evidence obligations to disentangle the device-specific effect from benefits arising from the enhanced supportive care associated with device delivery. This distinction is considered particularly important in populations with poor prognosis, where increased clinical attention and supportive care alone may improve outcomes.
The review highlights keywords and areas of application including glioblastoma, lung cancer, pancreatic cancer, sham-control, control arm, and tumor treating fields. It frames the need for stronger trial methodology and post-market transparency as essential to determine the extent to which observed clinical benefits derive from the electrical field intervention itself versus the broader package of care that accompanies TTF use.
Note: The content and conclusions above reflect the information reported in the PubMed abstract and article metadata. Detailed trial-level data, specific protocol amendment descriptions, and exact censoring patterns were not provided in the abstract and are not reported here.